DrugCombination product
Nanatinostat clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
- CHR-3996
- 1
Studies by the year they started
3 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2018 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses nanatinostat is read from its arms, and is right about nine times in ten.
Testing it · 3
- Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid MalignanciesCompletedPhase 1/2Viracta Therapeutics, Inc.NCT03397706Written as VRx-3996 and valganciclovir
- A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced CancersTerminatedPhase 1Viracta Therapeutics, Inc.NCT06302140Written as [14C]-Nanatinostat
- Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid TumoursCompletedPhase 1Chroma TherapeuticsNCT00697879Written as CHR-3996
Given in every arm · 1 — nanatinostat is usual care beside what is tested
Codes
What other systems call nanatinostat · ClinicalTrials.gg INT005766
- UNII (FDA) YTL7A418KQNANATINOSTATOne source FDA
- NCI Thesaurus C78475NanatinostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YTL7A418KQ | NANATINOSTAT | One source FDA |
| NCI Thesaurus | C78475 | Nanatinostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.